Menu
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et. Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et.
Selective Acetyl-CoA Carboxylase 2 (ACC2) inhibition to improve insulin sensitivity in patients with type 2 diabetes
LXR inverse agonist TLC-2716
Mitochondrial protonophore TLC-6740
Mitochondrial protonophore TLC-6740
Mitochondrial protonophore TLC-6740
Selective Acetyl-CoA Carboxylase 2 (ACC2) inhibition to improve insulin sensitivity in patients with type 2 diabetes
LXR inverse agonist TLC-2716
Mitochondrial protonophore TLC-6740
Mitochondrial protonophore TLC-6740
Mitochondrial protonophore TLC-6740
Selective Acetyl-CoA Carboxylase 2 (ACC2) inhibition to improve insulin sensitivity in patients with type 2 diabetes
LXR inverse agonist TLC-2716
Mitochondrial protonophore TLC-6740
Mitochondrial protonophore TLC-6740
Mitochondrial protonophore TLC-6740
Selective Acetyl-CoA Carboxylase 2 (ACC2) inhibition to improve insulin sensitivity in patients with type 2 diabetes
LXR inverse agonist TLC-2716
Mitochondrial protonophore TLC-6740
Mitochondrial protonophore TLC-6740
Mitochondrial protonophore TLC-6740
Selective Acetyl-CoA Carboxylase 2 (ACC2) inhibition to improve insulin sensitivity in patients with type 2 diabetes
LXR inverse agonist TLC-2716
Mitochondrial protonophore TLC-6740
Mitochondrial protonophore TLC-6740
Mitochondrial protonophore TLC-6740